Benitec Biopharma (FRA:BJ93) Cyclically Adjusted FCF per Share: €-13.72 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BJ93 Benitec Biopharma Inc FRA:BJ93
33 GF Score
Price €3.06
View Full Analysis

What is Benitec Biopharma Cyclically Adjusted FCF per Share?

Benitec Biopharma FRA:BJ93 33 Cyclically Adjusted FCF per Share is €-13.72 as of Mar. 2026. GuruFocus rates FRA:BJ93 with a GF Score™ of 33/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Benitec Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.078. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-13.72 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-29), Benitec Biopharma's current stock price is €3.06. Benitec Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-13.72. Benitec Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Benitec Biopharma  (FRA:BJ93) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Benitec Biopharma Cyclically Adjusted FCF per Share Related Terms


Benitec Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma Cyclically Adjusted FCF per Share Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -23.93 -13.23

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.09 -13.23 -10.80 -10.87 -13.72

FRA:BJ93 vs EDIT, AUTL, TENX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Benitec Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:BJ93
33GF Score
Benitec Biopharma Inc FRA:BJ93
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Benitec Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.078/330.2130*330.2130
=-0.078

Current CPI (Mar. 2026) = 330.2130.

Benitec Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.924 241.018 -2.636
201609 -6.398 241.428 -8.751
201612 -4.063 241.432 -5.557
201703 1.699 243.801 2.301
201706 -2.265 244.955 -3.053
201709 -2.541 246.819 -3.400
201712 -4.136 246.524 -5.540
201803 0.341 249.554 0.451
201806 -41.318 251.989 -54.144
201809 5.845 252.439 7.646
201812 -25.608 251.233 -33.658
201903 1.349 254.202 1.752
201906 -35.460 256.143 -45.714
201909 -9.706 256.759 -12.483
201912 -45.377 256.974 -58.310
202003 -11.048 258.115 -14.134
202006 -42.969 257.797 -55.039
202009 -33.092 260.280 -41.983
202012 -11.372 260.474 -14.417
202103 -6.036 264.877 -7.525
202106 -8.655 271.696 -10.519
202109 -7.559 274.310 -9.099
202112 -6.152 278.802 -7.286
202203 -6.459 287.504 -7.418
202206 -9.549 296.311 -10.642
202209 -6.393 296.808 -7.113
202212 -3.403 296.797 -3.786
202303 -2.286 301.836 -2.501
202306 -2.298 305.109 -2.487
202309 -1.988 307.789 -2.133
202312 -1.910 306.746 -2.056
202403 -0.310 312.332 -0.328
202406 -0.118 314.175 -0.124
202409 -0.148 315.301 -0.155
202412 -0.197 315.605 -0.206
202503 -0.074 319.799 -0.076
202506 -0.173 322.561 -0.177
202509 -0.069 324.800 -0.070
202512 -0.070 324.054 -0.071
202603 -0.078 330.213 -0.078

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-13.72 mean?
Benitec Biopharma (FRA:BJ93) has a Cyclically Adjusted FCF per Share of €-13.72 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Benitec Biopharma and its competitors.
Is Benitec Biopharma's Cyclically Adjusted FCF per Share too high?
Benitec Biopharma's current Cyclically Adjusted FCF per Share is €-13.72. Overall, Benitec Biopharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's Cyclically Adjusted FCF per Share compare to EDIT and AUTL?
Benitec Biopharma's Cyclically Adjusted FCF per Share of €-13.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current Cyclically Adjusted FCF per Share is €-13.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (FRA:BJ93) has a current Cyclically Adjusted FCF per Share of €-13.72. The current Cyclically Adjusted FCF per Share is €-13.72. Benitec Biopharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Benitec Biopharma (FRA:BJ93), the current Cyclically Adjusted FCF per Share is €-13.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Other Exchanges BNTC:USA
Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
33GF Score

Get the complete analysis for FRA:BJ93

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price